Synthetic RNA

Ainos SRNA Research Initiative

The success of messenger RNA (mRNA) COVID-19 vaccines set a promising future for synthetic RNA (SRNA) to speed up pharmaceutical innovation. We are establishing a synthetic RNA (SRNA) technology platform capable of producing messenger RNAs (mRNAs) and/or short inhibitory RNAs (siRNAs) for potential vaccine development and disease treatment.

Now is the Best Time to Pursue sRNA

Now is the Best Time to Pursue SRNA

There has never been a better time to redefine the future of medicine than through the ability to rapidly produce novel and personalize drugs for clinical and inherited diseases through SRNA. Although the clinical implementation of SRNAs as drugs to treat human diseases is still rare, we believe this is changing as the clinical application of mRNAs is proving to be successful in expressing functional protein antigens and inducing protective neutralizing antibodies against the SARS-CoV-2 virus.

As RNA's fabrication, purification, and cellular delivery technologies continue to advance, we anticipate increased interest in using RNA-based vaccines or therapeutics to treat various human diseases for two reasons. First, SRNAs are cost-effective and simple to manufacture. Second, SRNAs can be rapidly developed as personalized drugs for most clinical and inherited diseases.

The mRNA-based vaccines are gaining massive prominence for preventing SARS-CoV-2. mRNA's advantages include high efficacy, safety, reliability, less manufacturing time, and the ability to protect individuals against infections of new SARS-CoV-2 mutant strains, among others.

Research And Markets projects the global mRNA therapeutics markets should grow from $46.7 billion in 2021 to $101.3 billion in 2026, at a compound annual growth rate (CAGR) of 16.8% over 2021-2026.

Our Goals

Due to the continuous outbreaks and the emergent SARS-CoV-2 variants, our short-term goal focuses on developing 2nd generation SARS-CoV-2 vaccines using a synthetic mRNA-based platform. We will use the full-length spike gene sequence of the British alpha variant (lineage B1.1.7) and the Indian delta variant (lineage B.1.617.2) as reference sequences to generate mRNA vaccines with six proline mutations .

We also plan to adopt sequence modifications and codon optimization of the mRNA vaccines. We will test vaccine delivery with a liposome of known formulation and evaluate the immunization through intramuscular (systemic) and nasal (mucosal) routs in mice. We anticipate the research will generate a T helper 1 (Th1) biased immune response with potent neutralization antibody and effector CD8 T cell response. In addition, relevant recombinant spike proteins will be produced in Baculovirus expression systems. These proteins can be used as alternative immunogens, immunostimulatory adjuvants, or antigens to develop therapeutic monoclonal antibodies.

Our long-term vision is to enable the treatment of inflammatory diseases and cancers. We will generate mRNAs and/or siRNAs critical for immune modulations or tumor suppression. These mRNAs may express tumor suppressors, cancer-associated antigens, or immune agonists, while siRNAs may be used to degrade disease-associated genes of aberrant expression.

We plan to focus on the research and development of the technology. In addition, we intend to explore strategic partnership opportunities upon completion of phase 1 clinical trial(s)


United States:

8880 Rio San Diego Drive, Suite 800, San Diego, CA 92108

 +1 (858) 869-2986


10F-2, No. 66, Shengyi 5th Rd., Zhubei City, Hsinchu County 302 , Taiwan (R.O.C.)

 +886 (0)3-550-5199